Online citations, reference lists, and bibliographies.
← Back to Search

Drug Resistance By Evasion Of Antiangiogenic Targeting Of VEGF Signaling In Late-stage Pancreatic Islet Tumors.

O. Casanovas, D. Hicklin, G. Bergers, D. Hanahan
Published 2005 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Function-blocking antibodies to VEGF receptors R1 and R2 were used to probe their roles in controlling angiogenesis in a mouse model of pancreatic islet carcinogenesis. Inhibition of VEGFR2 but not VEGFR1 markedly disrupted angiogenic switching, persistent angiogenesis, and initial tumor growth. In late-stage tumors, phenotypic resistance to VEGFR2 blockade emerged, as tumors regrew during treatment after an initial period of growth suppression. This resistance to VEGF blockade involves reactivation of tumor angiogenesis, independent of VEGF and associated with hypoxia-mediated induction of other proangiogenic factors, including members of the FGF family. These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition.
This paper references
10.1016/S1476-5586(03)80047-7
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.
N. Cheng (2003)
10.1093/ANNONC/MDG033
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.
K. Miller (2003)
10.1113/jphysiol.1952.sp004789
Vascular reactions to histamine, histamine‐liberator and leukotaxine in the skin of guinea‐pigs
A. Miles (1952)
10.1073/PNAS.85.23.9037
Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene.
S. Efrat (1988)
10.1038/35036374
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G. Bergers (2000)
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.
F. Pezzella (1997)
10.1016/S1535-6108(02)00031-4
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.
M. Inoue (2002)
10.1158/0008-5472.CAN-04-3444
CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.
D. Daniel (2005)
Methods in laboratory investigation: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor
A. Passaniti (1992)
10.1038/sj.onc.1208602
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer
J. Joyce (2005)
10.1073/PNAS.91.14.6707
T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus.
C. Jolicoeur (1994)
10.1210/MEND.9.12.8614412
Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis.
G. Christofori (1995)
Fibroblast growth factors are required for efficient tumor angiogenesis.
A. Compagni (2000)
10.1038/nm0603-669
The biology of VEGF and its receptors
N. Ferrara (2003)
10.1016/S1535-6108(04)00111-4
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.
J. Joyce (2004)
10.1073/PNAS.95.16.9349
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.
S. Hiratsuka (1998)
10.1038/315115A0
Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes
D. Hanahan (1985)
10.1158/1078-0432.CCR-04-0823
Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option
W. Leenders (2004)
10.1016/J.CCR.2005.04.014
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
K. D. de Visser (2005)
10.1023/A:1013172910858
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
R. Kerbel (2004)
10.1002/ijc.10074
Transformation of the microvascular system during multistage tumorigenesis
E. Ryschich (2002)
10.1016/S1368-7646(03)00026-8
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.
H. Broxterman (2003)
A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.
A. Passaniti (1992)
10.1038/nm731
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
A. Luttun (2002)
10.1038/sj.onc.1205679
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo
D. Brantley (2002)
10.1016/S0092-8674(00)80108-7
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
D. Hanahan (1996)
10.1126/SCIENCE.284.5422.1994
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.
J. Holash (1999)
10.1247/CSF.26.25
Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.
M. Shibuya (2001)
10.1016/0092-8674(92)90030-G
RAG-1-deficient mice have no mature B and T lymphocytes
P. Mombaerts (1992)
10.1007/3-7643-7311-3_7
Can tumor angiogenesis be inhibited without resistance?
K. Miller (2005)
10.1182/BLOOD.V97.3.785
Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans.
A. Sawano (2001)
10.1126/SCIENCE.1068327
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
J. Yu (2002)
10.1172/jci8829c1
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
G. Klement (2000)
10.1016/S1535-6108(03)00085-0
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
S. Pennacchietti (2003)
10.1172/JCI17929
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
G. Bergers (2003)
10.1038/325223A0
Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells
T. Adams (1987)
10.1006/BBRC.1994.2726
Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor.
M. Dougher-Vermazen (1994)
10.1016/S1471-4914(03)00021-2
Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization.
S. Rabbany (2003)
10.1038/nm740
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
K. Hattori (2002)
10.1056/NEJMOA032691
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
10.1056/NEJMOA021491
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
J. Yang (2003)
10.1084/jem.20021047
Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells
D. Daniel (2003)
10.1126/SCIENCE.284.5415.808
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
G. Bergers (1999)
10.1038/nm0703-822
Angiogenesis inhibitors: motivators of metastasis?
P. Steeg (2003)
10.1038/nm0603-677
Regulation of angiogenesis by hypoxia: role of the HIF system
C. Pugh (2003)
10.1038/sj.emboj.7600709
VEGF receptor‐2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis
T. Matsumoto (2005)
10.1073/PNAS.93.5.2002
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
S. Parangi (1996)



This paper is referenced by
10.1111/cas.12409
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
T. Nakagawa (2014)
10.2436/cs.v9i1.83129
Anti-angiogenic therapy for cancer and the mechanisms of tumor resistance
Gabriela Jiménez-Valerio (2013)
Signalling Pathways in Cancer-VEGF
K. Badawi (2016)
10.1158/0008-5472.CAN-14-3773
Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
F. Kuhnert (2015)
Genetically engineered fusion proteins for treatment of cancer.
U. Weidle (2012)
10.1016/J.BBRC.2006.03.183
HGF-induced capillary morphogenesis of endothelial cells is regulated by Src.
S. Kanda (2006)
The Pharmacological Effect of Two Antibody Drugs for the Treatment of Tumor Metastasis
K. Kashima (2016)
10.1002/cbin.10397
HGF expression induced by HIF‐1α promote the proliferation and tube formation of endothelial progenitor cells
F. Yu (2015)
10.18632/oncotarget.7550
Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas
N. Cortes-Santiago (2016)
10.1016/j.canlet.2013.12.004
Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression.
D. Li (2014)
10.2217/fon.14.74
Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.
Greg A Durm (2014)
10.1053/j.seminoncol.2014.02.007
Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.
K. Mittal (2014)
10.1016/j.semcancer.2018.06.002
The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
Rindert Missiaen (2018)
10.1177/1758834014543794
Targeting angiogenesis in advanced cervical cancer
R. Eskander (2014)
10.1016/j.ejphar.2011.06.015
Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate.
J. Angulo (2011)
10.1038/onc.2015.236
Endothelial CXCR7 Regulates Breast Cancer Metastasis
Amanda C. Stacer (2016)
10.1016/j.cell.2007.08.038
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Christian Fischer (2007)
10.1021/jm701397k
7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
R. Frey (2008)
10.1093/carcin/bgn204
Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.
C. Maillard (2008)
10.1016/j.cytogfr.2009.11.003
Pathways mediating VEGF-independent tumor angiogenesis.
N. Ferrara (2010)
10.1007/978-1-4419-0751-6_26
Biologic and Systemic Therapies for the Treatment of Hepatocellular Carcinoma
Richard S. Finn (2013)
10.1101/cshperspect.a006569
VEGF and Notch in tip and stalk cell selection.
Raquel Blanco (2013)
Membrane-type matrix metalloproteinases in pericellular proteolysis and melanoma cell invasion
Olga Tatti (2013)
10.4236/JCT.2013.48A006
Advances in Lung Cancer and Treatment Research
Xiaofei Wang (2013)
10.1007/978-2-8178-0430-9_12
Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment
Annemilaï Tijeras-Raballand (2014)
10.1016/j.ccell.2015.07.002
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
R. Ronca (2015)
10.1056/NEJMra0706596
Tumor angiogenesis.
R. Kerbel (2008)
Role of IL 13 RA 2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
N. Shibasaki (2018)
Explorer Stimulation of Tumor Relapse After Chemotherapy by Perivascular , Alternatively Activated Macrophages
Russell Hughes (2015)
10.1097/COC.0000000000000492
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients
W. Ma (2019)
10.1215/15228517-2008-117
MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model.
S. Valable (2009)
10.18926/AMO/47260
Targeting angiogenesis in cancer therapy.
E. Ichihara (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar